Enveric Biosciences, a Cambridge, Massachusetts biotech, closed a private placement that could raise up to $13.9 million.
The capital will fund Enveric’s neuroplastogenic small‑molecule programs—targeting psychiatric and neurological disorders.
Funding gaps in this space often delay clinical progress, so the raise is significant for investors and patients alike.
The company received $5 million in cash at closing[1] and issued warrants that could generate an additional $8.9 million if exercised[1], bringing total possible proceeds to $13.9 million[1].
Enveric sold 2.22 million shares, some in the form of pre‑funded warrants[3], and granted Series I and short‑term Series J warrants[3] with an exercise price of $2 per share[3].
The warrants are priced at‑the‑market under Nasdaq rules, allowing investors to purchase shares at prevailing prices while giving the company immediate access to capital[2].
Enveric plans to allocate the funds to preclinical studies, IND‑enabling work, and early‑stage clinical trials for its lead candidates, which target synaptic plasticity pathways believed to restore neural function.
The financing moves the company closer to its next funding milestone and may attract further institutional interest as the biotech market seeks novel approaches to mental‑health treatment.
Analysts note that the $5 million upfront reduces short‑term cash‑flow pressure, while the contingent $8.9 million provides upside if the pipeline advances and warrants are exercised.
Enveric’s board approved the placement in a meeting held in Cambridge, and the transaction was filed with the SEC under Nasdaq Rule 504.
The company previously raised $15 million in a Series B round in 2024, which financed its first IND filing. The new private placement complements that capital base and signals confidence from private investors.
Biotech firms developing small‑molecule neuroplasticity agents have seen heightened investor interest following recent FDA approvals of similar mechanisms, making Enveric’s raise timely amid a competitive pipeline landscape.
While the total potential proceeds are capped at $13.9 million, the actual amount will depend on warrant exercise, which is tied to the company’s share price performance and trial milestones.
Investors will watch Enveric’s upcoming Q3 data release, where the firm expects to report preclinical efficacy results for its lead candidate, Enver‑101, a molecule designed to enhance dendritic spine formation.
If the data meet expectations, the company could see increased warrant exercises, boosting its cash runway and positioning it for a potential public offering or larger private round later this year.
“$5 million in cash was received at closing.”
The placement gives Enveric immediate liquidity and a contingent financing runway tied to its share price, reducing short‑term funding risk while preserving upside if its neuroplastogenic pipeline progresses, a key factor for future growth and potential public market positioning.
